TVTX
Travere Therapeutics, Inc.$27.29-0.62 (-2.24%)Prev Close$27.72·MCap$2.66B·P/E—·Vol203.8K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
38
$23.76M
◆
Net Activity
Net Seller
$23.76M
●
Active Insiders
8
last 12 mo
Over the past 12 months, insider activity at Travere Therapeutics, Inc. (TVTX) has been exclusively selling, with 0 insider purchases totaling $0.00 and 38 insider sales totaling $23.76M. The most recent insider transaction was by REED ELIZABETH E (officer: Chief Legal Officer and GC), who sold $280.9K worth of shares on Mar 18, 2026. Travere Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $2.66B.
TVTX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 10,000 | $28.09 | $280.9K | 105,211 |
| Feb 24, 2026 | Dube Eric M | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 120,000 | $30.10 | $3.61M | 432,886 |
| Feb 19, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 10,000 | $27.83 | $278.3K | 109,532 |
| Feb 17, 2026 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 10,000 | $27.83 | $278.3K | 0 |
| Feb 5, 2026 | Cline Christopher R. | officer: CHIEF FINANCIAL OFFICER | Sell | 1,745 | $32.19 | $56.2K | 111,336 |
| Feb 5, 2026 | Inrig Jula | officer: CHIEF MEDICAL OFFICER | Sell | 1,779 | $32.21 | $57.3K | 105,938 |
| Feb 5, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 2,994 | $32.18 | $96.4K | 105,720 |
| Feb 3, 2026 | Calvin Sandra | officer: SVP, CHIEF ACCOUNTING OFFICER | Sell | 4,333 | $32.12 | $139.2K | 49,080 |
| Feb 3, 2026 | Cline Christopher R. | officer: CHIEF FINANCIAL OFFICER | Sell | 7,242 | $32.12 | $232.6K | 112,971 |
| Feb 3, 2026 | Dube Eric M | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 100,087 | $32.28 | $3.23M | 466,521 |
| Feb 3, 2026 | Heerma Peter | officer: CHIEF COMMERCIAL OFFICER | Sell | 7,310 | $32.12 | $234.8K | 131,823 |
| Feb 3, 2026 | Inrig Jula | officer: CHIEF MEDICAL OFFICER | Sell | 6,956 | $32.12 | $223.4K | 107,485 |
| Feb 3, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 7,175 | $32.12 | $230.5K | 108,205 |
| Feb 3, 2026 | ROTE WILLIAM E. | officer: Chief Research Officer | Sell | 12,446 | $32.87 | $409.1K | 109,087 |
| Jan 27, 2026 | Dube Eric M | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 60,000 | $30.09 | $1.81M | 419,173 |
| Jan 21, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 10,000 | $27.34 | $273.4K | 90,270 |
| Jan 7, 2026 | Inrig Jula | officer: CHIEF MEDICAL OFFICER | Sell | 2,476 | $39.74 | $98.4K | 86,756 |
| Dec 29, 2025 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 7,402 | $40.00 | $296.1K | 38,233 |
| Dec 29, 2025 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 4,980 | $40.00 | $199.2K | 113,013 |
| Dec 29, 2025 | Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 15,000 | $42.00 | $630.0K | 88,787 |
| Dec 29, 2025 | ROTE WILLIAM E. | Chief Research Officer | Sell | 60,000 | $40.10 | $2.41M | 101,443 |
| Dec 16, 2025 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 2,910 | $36.00 | $104.8K | 45,635 |
| Dec 3, 2025 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 20,000 | $35.01 | $700.2K | 92,083 |
| Nov 6, 2025 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 67,115 | $36.00 | $2.42M | 48,545 |
| Nov 4, 2025 | Coughlin Timothy | Sell | 18,000 | $35.03 | $630.6K | 55,500 | |
| Nov 4, 2025 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 5,591 | $35.00 | $195.7K | 119,071 |
| Oct 30, 2025 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 120,000 | $30.32 | $3.64M | 419,173 |
| Oct 30, 2025 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 2,662 | $30.00 | $79.9K | 124,662 |
| Sep 24, 2025 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 10,000 | $25.00 | $250.0K | 89,878 |
| Sep 5, 2025 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 573 | $18.51 | $10.6K | 92,202 |
| Aug 28, 2025 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 470 | $17.31 | $8.1K | 92,656 |
| Jul 2, 2025 | Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 815 | $14.65 | $11.9K | 88,787 |
| May 5, 2025 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 1,784 | $21.05 | $37.6K | 93,126 |
| May 5, 2025 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 18,924 | $21.05 | $398.4K | 419,173 |
| May 5, 2025 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 1,771 | $21.05 | $37.3K | 128,215 |
| May 5, 2025 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 4,920 | $21.05 | $103.6K | 89,482 |
| May 5, 2025 | ROTE WILLIAM E. | Chief Research Officer | Sell | 3,198 | $21.05 | $67.3K | 100,241 |
| Apr 14, 2025 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 48 | $13.14 | $630.94 | 89,990 |
| Feb 12, 2025 | Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 2,568 | $23.53 | $60.4K | 89,602 |
| Feb 12, 2025 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 34,244 | $25.00 | $856.1K | 63,654 |
| Feb 12, 2025 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 11,375 | $24.04 | $273.5K | 419,173 |
| Feb 12, 2025 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 5,642 | $24.33 | $137.3K | 127,634 |
| Feb 12, 2025 | REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY | Sell | 8,000 | $23.53 | $188.2K | 89,482 |
| Feb 12, 2025 | ROTE WILLIAM E. | SENIOR VICE PRESIDENT, R&D | Sell | 5,200 | $23.53 | $122.4K | 98,519 |
| Feb 10, 2025 | Baynes Roy D. | Sell | 10,000 | $22.00 | $220.0K | 31,000 | |
| Feb 4, 2025 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 3,348 | $20.12 | $67.4K | 63,654 |
| Feb 4, 2025 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 5,192 | $20.12 | $104.5K | 90,038 |
| Feb 4, 2025 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 50,691 | $20.21 | $1.02M | 430,548 |
| Feb 4, 2025 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 5,166 | $20.12 | $103.9K | 122,708 |
| Feb 4, 2025 | Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 5,273 | $20.12 | $106.1K | 85,236 |
Showing 1–50 of 155
1 / 4
TVTX Insider Buying Activity
The following table shows recent insider purchases of Travere Therapeutics, Inc. (TVTX) stock reported via SEC Form 4 filings.
No insider buying activity found for TVTX in the last 12 months.
TVTX Insider Selling Activity
The following table shows recent insider sales of Travere Therapeutics, Inc. (TVTX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 10,000 | $28.09 | $280.9K | 105,211 |
| Feb 24, 2026 | Dube Eric M | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 120,000 | $30.10 | $3.61M | 432,886 |
| Feb 19, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 10,000 | $27.83 | $278.3K | 109,532 |
| Feb 17, 2026 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 10,000 | $27.83 | $278.3K | 0 |
| Feb 5, 2026 | Cline Christopher R. | officer: CHIEF FINANCIAL OFFICER | Sell | 1,745 | $32.19 | $56.2K | 111,336 |
| Feb 5, 2026 | Inrig Jula | officer: CHIEF MEDICAL OFFICER | Sell | 1,779 | $32.21 | $57.3K | 105,938 |
| Feb 5, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 2,994 | $32.18 | $96.4K | 105,720 |
| Feb 3, 2026 | Calvin Sandra | officer: SVP, CHIEF ACCOUNTING OFFICER | Sell | 4,333 | $32.12 | $139.2K | 49,080 |
| Feb 3, 2026 | Cline Christopher R. | officer: CHIEF FINANCIAL OFFICER | Sell | 7,242 | $32.12 | $232.6K | 112,971 |
| Feb 3, 2026 | Dube Eric M | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 100,087 | $32.28 | $3.23M | 466,521 |
| Feb 3, 2026 | Heerma Peter | officer: CHIEF COMMERCIAL OFFICER | Sell | 7,310 | $32.12 | $234.8K | 131,823 |
| Feb 3, 2026 | Inrig Jula | officer: CHIEF MEDICAL OFFICER | Sell | 6,956 | $32.12 | $223.4K | 107,485 |
| Feb 3, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 7,175 | $32.12 | $230.5K | 108,205 |
| Feb 3, 2026 | ROTE WILLIAM E. | officer: Chief Research Officer | Sell | 12,446 | $32.87 | $409.1K | 109,087 |
| Jan 27, 2026 | Dube Eric M | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 60,000 | $30.09 | $1.81M | 419,173 |
| Jan 21, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 10,000 | $27.34 | $273.4K | 90,270 |
| Jan 7, 2026 | Inrig Jula | officer: CHIEF MEDICAL OFFICER | Sell | 2,476 | $39.74 | $98.4K | 86,756 |
| Dec 29, 2025 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 7,402 | $40.00 | $296.1K | 38,233 |
| Dec 29, 2025 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 4,980 | $40.00 | $199.2K | 113,013 |
| Dec 29, 2025 | Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 15,000 | $42.00 | $630.0K | 88,787 |
| Dec 29, 2025 | ROTE WILLIAM E. | Chief Research Officer | Sell | 60,000 | $40.10 | $2.41M | 101,443 |
| Dec 16, 2025 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 2,910 | $36.00 | $104.8K | 45,635 |
| Dec 3, 2025 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 20,000 | $35.01 | $700.2K | 92,083 |
| Nov 6, 2025 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 67,115 | $36.00 | $2.42M | 48,545 |
| Nov 4, 2025 | Coughlin Timothy | Sell | 18,000 | $35.03 | $630.6K | 55,500 | |
| Nov 4, 2025 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 5,591 | $35.00 | $195.7K | 119,071 |
| Oct 30, 2025 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 120,000 | $30.32 | $3.64M | 419,173 |
| Oct 30, 2025 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 2,662 | $30.00 | $79.9K | 124,662 |
| Sep 24, 2025 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 10,000 | $25.00 | $250.0K | 89,878 |
| Sep 5, 2025 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 573 | $18.51 | $10.6K | 92,202 |
| Aug 28, 2025 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 470 | $17.31 | $8.1K | 92,656 |
| Jul 2, 2025 | Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 815 | $14.65 | $11.9K | 88,787 |
| May 5, 2025 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 1,784 | $21.05 | $37.6K | 93,126 |
| May 5, 2025 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 18,924 | $21.05 | $398.4K | 419,173 |
| May 5, 2025 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 1,771 | $21.05 | $37.3K | 128,215 |
| May 5, 2025 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 4,920 | $21.05 | $103.6K | 89,482 |
| May 5, 2025 | ROTE WILLIAM E. | Chief Research Officer | Sell | 3,198 | $21.05 | $67.3K | 100,241 |
| Apr 14, 2025 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 48 | $13.14 | $630.94 | 89,990 |
| Feb 12, 2025 | Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 2,568 | $23.53 | $60.4K | 89,602 |
| Feb 12, 2025 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 34,244 | $25.00 | $856.1K | 63,654 |
| Feb 12, 2025 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 11,375 | $24.04 | $273.5K | 419,173 |
| Feb 12, 2025 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 5,642 | $24.33 | $137.3K | 127,634 |
| Feb 12, 2025 | REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY | Sell | 8,000 | $23.53 | $188.2K | 89,482 |
| Feb 12, 2025 | ROTE WILLIAM E. | SENIOR VICE PRESIDENT, R&D | Sell | 5,200 | $23.53 | $122.4K | 98,519 |
| Feb 10, 2025 | Baynes Roy D. | Sell | 10,000 | $22.00 | $220.0K | 31,000 | |
| Feb 4, 2025 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 3,348 | $20.12 | $67.4K | 63,654 |
| Feb 4, 2025 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 5,192 | $20.12 | $104.5K | 90,038 |
| Feb 4, 2025 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 50,691 | $20.21 | $1.02M | 430,548 |
| Feb 4, 2025 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 5,166 | $20.12 | $103.9K | 122,708 |
| Feb 4, 2025 | Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 5,273 | $20.12 | $106.1K | 85,236 |
TVTX Insiders
Similar Stocks to TVTX
VRTX
Vertex Pharmaceuticals Incorporated
$458.04-0.20%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$739.34+0.22%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$319.02+2.37%
$42.07B
INSM
Insmed Incorporated
$141.70-1.72%
$30.07B
UTHR
United Therapeutics Corporation
$525.04-0.36%
$23.50B
MRNA
Moderna, Inc.
$52.42+0.02%
$20.76B
ROIV
Roivant Sciences Ltd.
$27.54-1.08%
$20.08B
RPRX
Royalty Pharma plc
$45.12-1.03%
$19.56B